<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115349</article-id><article-id pub-id-type="publisher-id">ACM-42761</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_83331948.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胱抑素C在肝移植术后急性肾损伤患者中的研究
  Cystatin C in Patients with Acute Kidney Injury after Liver Transplantation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>晓蒙</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>通旺</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>代</surname><given-names>增强</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>鹏翔</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>德喜</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>青岛大学医学部，山东 青岛；青岛大学附属医院器官移植中心，山东 青岛；首都医科大学附属佑安医院北京市肝病研究所，北京</addr-line></aff><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛；青岛大学附属医院器官移植中心，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院器官移植中心，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2422</fpage><lpage>2428</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨胱抑素C (CysC)在肝移植术后患者急性肾损伤(AKI)早期诊断中的价值。方法：回顾性分析青岛大学附属医院肝脏移植科2018年1月~2019年1月行肝脏移植术的术前肾功能正常患者的临床资料。应用改善全球肾脏病预后组织(KDIGO) 2012年修订的AKI诊断和分期标准，并根据肝移植术后是否发生AKI将患者分为两组：急性肾损伤和非急性肾损伤组。收集术前患者一般资料以及术前、术后第1、2、3天CysC数值，采用ROC曲线评价Cys C对肝移植术后急性肾损伤的诊断价值。结果：本研究共纳入110例肝移植患者，术后57例发生AKI (51.8%)。结果显示，急性肾损伤组术前及术后第1、2、3天Cys C数值与对照组比较，有统计学差异。ROC曲线结果显示，采用术前Cys C为早期诊断指标，Cys C的最佳截断值为0.98 mg/L。结论：Cys C可作为术前肾功能正常患者肝移植术后发生急性肾损伤的内源性标志物。对于术前Cys C增高的患者，应注意预防术后急性肾损伤的发生。
   Objective: To investigate the value of Cys C in the early diagnosis of acute kidney injury after liver transplantation. Method: To retrospectively analyze the clinical data of patients with normal renal function who underwent liver transplantation in the Department of liver transplantation, Affiliated Hospital of Qingdao University from January 2018 to January 2019. According to the diagnostic and staging criteria of AKI revised by the global organization for improving the prognosis of kidney disease (KDIGO) in 2012, the patients were divided into two groups: acute kidney injury group and non acute kidney injury group. The general data of patients before operation and serum CysC values before operation and on the 1st, 2nd and 3rd day after operation were collected. The diagnostic value of CysC for acute kidney injury after liver transplantation was evaluated by ROC curve. Result: A total of 110 patients with liver transplantation were included in this study. AKI occurred in 57 patients (51.8%). The results showed that there were significant differences in Cys C values between the acute kidney injury group and the control group before operation and on the 1st, 2nd and 3rd day after operation. ROC curve results showed that the optimal cut-off value of Cys C was 0.98 mg/L using preoperative Cys C as an early diagnostic index. Conclusion: Cys C can be used as an endogenous marker of acute kidney injury in patients with normal preoperative renal function after liver transplantation. We should pay attention to the prevention of postoperative acute kidney injury in patients with preoperative cystatin increase.
 
</p></abstract><kwd-group><kwd>肝脏移植，急性肾损伤，胱抑素C，早期诊断, Liver Transplantation</kwd><kwd> Acute Kidney Injury</kwd><kwd> Cystatin C</kwd><kwd> Early Diagnosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨胱抑素C (CysC)在肝移植术后患者急性肾损伤(AKI)早期诊断中的价值。方法：回顾性分析青岛大学附属医院肝脏移植科2018年1月~2019年1月行肝脏移植术的术前肾功能正常患者的临床资料。应用改善全球肾脏病预后组织(KDIGO) 2012年修订的AKI诊断和分期标准，并根据肝移植术后是否发生AKI将患者分为两组：急性肾损伤和非急性肾损伤组。收集术前患者一般资料以及术前、术后第1、2、3天CysC数值，采用ROC曲线评价Cys C对肝移植术后急性肾损伤的诊断价值。结果：本研究共纳入110例肝移植患者，术后57例发生AKI (51.8%)。结果显示，急性肾损伤组术前及术后第1、2、3天Cys C数值与对照组比较，有统计学差异。ROC曲线结果显示，采用术前Cys C为早期诊断指标，Cys C的最佳截断值为0.98 mg/L。结论：Cys C可作为术前肾功能正常患者肝移植术后发生急性肾损伤的内源性标志物。对于术前Cys C增高的患者，应注意预防术后急性肾损伤的发生。</p></sec><sec id="s2"><title>关键词</title><p>肝脏移植，急性肾损伤，胱抑素C，早期诊断</p></sec><sec id="s3"><title>Cystatin C in Patients with Acute Kidney Injury after Liver Transplantation</title><p>Xiaomeng Yang<sup>1,2</sup>, Tongwang Yang<sup>2</sup>, Zengqiang Dai<sup>2</sup>, Pengxiang Yang<sup>1,2</sup>, Dexi Chen<sup>1,</sup><sup>2,3*</sup></p><p><sup>1</sup>Department of Medicine, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Organ Transplantation Center, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>3</sup>Institute of Liver Disease, You’an Hospital, Capital Medical University, Beijing</p><p><img src="//html.hanspub.org/file/58-1572165x5_hanspub.png" /></p><p>Received: Apr. 25<sup>th</sup>, 2021; accepted: May 8<sup>th</sup>, 2021; published: May 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/58-1572165x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the value of Cys C in the early diagnosis of acute kidney injury after liver transplantation. Method: To retrospectively analyze the clinical data of patients with normal renal function who underwent liver transplantation in the Department of liver transplantation, Affiliated Hospital of Qingdao University from January 2018 to January 2019. According to the diagnostic and staging criteria of AKI revised by the global organization for improving the prognosis of kidney disease (KDIGO) in 2012, the patients were divided into two groups: acute kidney injury group and non acute kidney injury group. The general data of patients before operation and serum CysC values before operation and on the 1st, 2nd and 3rd day after operation were collected. The diagnostic value of CysC for acute kidney injury after liver transplantation was evaluated by ROC curve. Result: A total of 110 patients with liver transplantation were included in this study. AKI occurred in 57 patients (51.8%). The results showed that there were significant differences in Cys C values between the acute kidney injury group and the control group before operation and on the 1st, 2nd and 3rd day after operation. ROC curve results showed that the optimal cut-off value of Cys C was 0.98 mg/L using preoperative Cys C as an early diagnostic index. Conclusion: Cys C can be used as an endogenous marker of acute kidney injury in patients with normal preoperative renal function after liver transplantation. We should pay attention to the prevention of postoperative acute kidney injury in patients with preoperative cystatin increase.</p><p>Keywords:Liver Transplantation, Acute Kidney Injury, Cystatin C, Early Diagnosis</p><disp-formula id="hanspub.42761-formula59"><graphic xlink:href="//html.hanspub.org/file/58-1572165x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/58-1572165x8_hanspub.png" /> <img src="//html.hanspub.org/file/58-1572165x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>肝移植目前已经是终末期肝病首选的治疗方法 [<xref ref-type="bibr" rid="hanspub.42761-ref1">1</xref>]。而肝移植术后急性肾损伤(acute kidney injury，AKI)作为术后常见并发症，也是移植术后死亡的主要原因之一 [<xref ref-type="bibr" rid="hanspub.42761-ref2">2</xref>]。既往有研究表明，即使在术前肾功能正常的患者中，肝移植术后早期AKI的发生率仍高达46.7% [<xref ref-type="bibr" rid="hanspub.42761-ref3">3</xref>]。血肌酐(SCr)是目前最常用于诊断AKI的血清标志物，但由于SCr易受年龄等各种方面影响，容易延误肾功不全的诊断，尤其在等待肝移植的患者中 [<xref ref-type="bibr" rid="hanspub.42761-ref4">4</xref>]。所以我们需要能早期预测肝移植术后AKI的指标。如果能早期发现并预防AKI的发生，并提前采取措施干预，能极大改善肝移植患者的预后。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>研究对象来自于我院肝脏移植科2018年1月~2018年12月行肝脏移植术的患者。所有患者均签署由本院伦理委员会批准的患者知情同意书，符合医学伦理学规定。入组标准：年龄大于等于18岁；行首次肝移植；临床资料完整。排除标准为：超紧急移植、术前肾功能不全或存在基础肾脏疾病、劈离式肝移植、联合器官移植、术后48 h内死亡或自动出院。</p></sec><sec id="s6_2"><title>2.2. 资料收集</title><p>回顾性收集患者资料，包括：1) 基线数据：收集患者性别、年龄、身高和体重等人口学资料；收集原发病、伴发基础疾病(高血压、糖尿病等)、既往手术史、合并症等；2) 术前情况：血红蛋白、尿素氮、SCr、CysC等生化指标；术前终末期肝病模型(model for end-stage liver disease, MELD)评分；3) 术后变量：术后第1、2、3天CysC值。</p></sec><sec id="s6_3"><title>2.3. AKI的诊断标准与分期及术语的定义</title><p>1) 患者入院后至手术前检测的血清肌酐平均水平为基线肌酐，应用KDIG02012年修订的AKI诊断和分期标准，符合以下任意1条即诊断AKI：48 h内血清SCr升高值 ≥ 26.5 μmol/L，或7 d内SCr上升至基线水平的1.5倍以上，或持续6 h尿量 &lt; 0.5 ml∙kg<sup>−1</sup>∙h<sup>−15</sup> [<xref ref-type="bibr" rid="hanspub.42761-ref5">5</xref>]。</p><p>肝移植术后早期AKI定义：术后7 d内发生的AKI。</p><p>2) 计算公式：</p><p>肝脏疾病严重程度：MELD评分：R = 3.8ln[胆红素(mg/dl)] + 11.2ln(INR) + 9.6ln [肌酐(mg/dl)] + 6.4*病因(病因：胆汁性或酒精性0，其他1)。</p></sec><sec id="s6_4"><title>2.4. 统计方法</title><p>正态分布的计量资料用均数 &#177; 标准差( x &#175; &#177; s)表示，非正态分布计量资料用中位数(四分位)表示。正态分布的计量资料两组间比较用独立样本t检验，非正态分布资料两组间比较用秩和检验。计数资料采用频数和率表示，组间比较采用卡方检验或Fisher精确检验。采用ROC曲线评估术前及术后第1、2、3天Cys C的数值对AKI的早期诊断价值。所有资料采用SPSS22.0软件进行分析统计，P &lt; 0.05被认为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 患者与方法</title><p>2018年1月~2018年12月在青岛大学附属医院接受肝移植术共127例患者，其中8名患者存在术前肾功能不全或存在基础肾脏疾病，6例行劈离式肝移植的患者，2例患者为二次肝移植，1例患者年龄小于18岁。将以上患者排除，共纳入110例终末期肝病患者.其中男性91例，女性19例。平均年龄52.6 &#177; 9.6岁。原发病：乙肝肝硬化合并肝细胞癌(肝癌) 58例、乙肝肝硬化25例、酒精性肝硬化12例，其他终末期肝病15例。根据术后有无AKI分为肾损伤组57例，非肾损伤组53例。对两组患者的基本信息进行统计，结果显示，两组患者的年龄、性别比、肌酐基础值、MELD评分、原发疾病等比较，均无统计学差异(P &gt; 0.05)，BMI结果显示有统计学差异(P &lt; 0.001)，见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general data between the two group</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >总人数(n = 110)</th><th align="center" valign="middle" >AKI组(n = 57)</th><th align="center" valign="middle" >非AKI组(n = 53)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >男性，[例(%)]</td><td align="center" valign="middle" >91 (82.7)</td><td align="center" valign="middle" >49 (86.0)</td><td align="center" valign="middle" >42 (79.3)</td><td align="center" valign="middle" >0.352</td></tr><tr><td align="center" valign="middle" >年龄( x &#175; &#177; SD，岁)</td><td align="center" valign="middle" >52.6 &#177; 9.6</td><td align="center" valign="middle" >53.2 &#177; 10.2</td><td align="center" valign="middle" >52.0 &#177; 8.9</td><td align="center" valign="middle" >0.544</td></tr><tr><td align="center" valign="middle" >BMI ( x &#175; &#177; SD, kg/m<sup>2</sup>)</td><td align="center" valign="middle" >24.1 &#177; 3.6</td><td align="center" valign="middle" >25.4 &#177; 3.7</td><td align="center" valign="middle" >22.8 &#177; 3.0</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >高血压，[例(%)]</th><th align="center" valign="middle" >17 (15.5)</th><th align="center" valign="middle" >12 (21.1)</th><th align="center" valign="middle" >5 (9.4)</th><th align="center" valign="middle" >0.092</th></tr></thead><tr><td align="center" valign="middle" >糖尿病，[例(%)]</td><td align="center" valign="middle" >18 (16.4)</td><td align="center" valign="middle" >8 (14.0)</td><td align="center" valign="middle" >10 (18.9)</td><td align="center" valign="middle" >0.866</td></tr><tr><td align="center" valign="middle" >肝性脑病，[例(%)]</td><td align="center" valign="middle" >11 (10.0)</td><td align="center" valign="middle" >7 (12.3)</td><td align="center" valign="middle" >4 (7.5)</td><td align="center" valign="middle" >0.408</td></tr><tr><td align="center" valign="middle" >腹水，[例(%)]</td><td align="center" valign="middle" >64 (58.2)</td><td align="center" valign="middle" >33 (57.9)</td><td align="center" valign="middle" >31 (58.5)</td><td align="center" valign="middle" >0.950</td></tr><tr><td align="center" valign="middle" >消化道出血，[例(%)]</td><td align="center" valign="middle" >35 (31.8)</td><td align="center" valign="middle" >13 (22.8)</td><td align="center" valign="middle" >22 (41.5)</td><td align="center" valign="middle" >0.035</td></tr><tr><td align="center" valign="middle" >手术史，[例(%)]</td><td align="center" valign="middle" >54 (49.1)</td><td align="center" valign="middle" >24 (42.1)</td><td align="center" valign="middle" >30 (56.6)</td><td align="center" valign="middle" >0.129</td></tr><tr><td align="center" valign="middle" >MELD评分，中位数(IR)</td><td align="center" valign="middle" >9.7 (7.2~15.1)</td><td align="center" valign="middle" >10.6 (8.2~15.6)</td><td align="center" valign="middle" >9.3 (6.8~13.6)</td><td align="center" valign="middle" >0.128</td></tr><tr><td align="center" valign="middle" >血红蛋白( x &#175; &#177; SD, g/L)</td><td align="center" valign="middle" >114.1 &#177; 30.1</td><td align="center" valign="middle" >118.2 &#177; 25.9</td><td align="center" valign="middle" >109.7 &#177; 33.7</td><td align="center" valign="middle" >0.144</td></tr><tr><td align="center" valign="middle" >肌酐( x &#175; &#177; SD, μmol/L)</td><td align="center" valign="middle" >55.2 &#177; 12.1</td><td align="center" valign="middle" >54.5 &#177; 11.6</td><td align="center" valign="middle" >56.1 &#177; 12.6</td><td align="center" valign="middle" >0.479</td></tr><tr><td align="center" valign="middle" >尿素氮，中位数(IR)，mmol/L</td><td align="center" valign="middle" >4.7 (3.6~5.7)</td><td align="center" valign="middle" >4.5 (3.6~6.0)</td><td align="center" valign="middle" >4.8 (3.6~5.6)</td><td align="center" valign="middle" >0.582</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 两组一般资料比较</p><p>AKI：急性肾损伤；BMI，体质量指数；MELD评分，终末期肝病模型评分。</p></sec><sec id="s7_2"><title>3.2. CysC诊断价值结果</title><p>对两组患者的CysC值进行统计并计算。结果显示，两组术前及第1、2、3天CysC数值比较，有统计学差异(P &lt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of cystatin C levels at different time points between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后第一天</th><th align="center" valign="middle" >术后第二天</th><th align="center" valign="middle" >术后第三天</th></tr></thead><tr><td align="center" valign="middle" >AKI组</td><td align="center" valign="middle" >1.14 &#177; 0.32</td><td align="center" valign="middle" >1.35 &#177; 0.47</td><td align="center" valign="middle" >1.76 &#177; 0.65</td><td align="center" valign="middle" >2.00 &#177; 0.86</td></tr><tr><td align="center" valign="middle" >非AKI组</td><td align="center" valign="middle" >1.00 &#177; 0.28</td><td align="center" valign="middle" >0.96 &#177; 0.22</td><td align="center" valign="middle" >1.15 &#177; 0.29</td><td align="center" valign="middle" >1.25 &#177; 0.28</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" >2.253</td><td align="center" valign="middle" >5.567</td><td align="center" valign="middle" >6.473</td><td align="center" valign="middle" >6.287</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表2. AKI组与非AKI组不同时刻胱抑素C水平比较</p></sec><sec id="s7_3"><title>3.3. 两组术后CysC值ROC曲线</title><p>据图1 ROC曲线结果显示，术前的ROC曲线下面积为0.652，术后第一天的ROC曲线下面积为0.774，术后第二天的ROC曲线下面积为0.828，术后第三天的ROC曲线下面积为0.843。根据ROC曲线面积结果及早期诊断价值，对于术前患者测量CysC的患者可选取最佳截断值为CysC ≥ 0.98 mg/L。而对于术后病人，术后第一天最佳截断值为CysC ≥ 1.10 mg/L。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>随着医学的发展，对于终末期肝病(ESLD)的患者，肝移植已成为首选的治疗方法。而随着手术方式、麻醉技术以及器官获取方式、免疫排斥方案的进步，肝移植的预后逐渐改善。然而，急性肾损伤目前仍是肝移植术后常见的危及生命的并发症之一。根据既往不同的移植中心的统计，由于标准的不同，平均发生率在60% (17%~95%)，术后早期行肾脏代替治疗(RRT)的比例为8%~17% [<xref ref-type="bibr" rid="hanspub.42761-ref2">2</xref>]。本研究中，移植术后AKI发生率为51.8%，与既往报道相符。肝移植术后的急性肾损伤，不仅会导致患者本次住院时间延长，感染等不良并发症几率增加，并且有研究显示，肝移植后的AKI会导致患者术后长期的预后不佳以及术后远期慢性肾脏病的发病率增高 [<xref ref-type="bibr" rid="hanspub.42761-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.42761-ref7">7</xref>]。因此肝移植术后的AKI早期诊断至关重要。</p><p>图1. 术前与术后1，2，3天的胱抑素C的ROC曲线</p><p>血清肌酐是目前最常用于诊断AKI的血清标志物，但是相比胱抑素C，SCr易受年龄、性别、肌肉质量、肝功能等的影响。既往有大量研究表明，术前肾功能不全是预测术后AKI的独立危险因素 [<xref ref-type="bibr" rid="hanspub.42761-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.42761-ref9">9</xref>]。然而，Scr评估肝移植患者术前肾功能和术后AKI具有滞后性，往往会高估患者目前的肾功能。因为肌酐所受影响因素多，Scr异常表明肾功能已经有潜在损害。而此时肾脏代偿能力差，如果再有外在肾损伤因素刺激，患者肾功能会急剧恶化，造成不可逆的肾损害。本研究选取肝移植术前肾功能正常的患者作为研究对象，排除了术前严重的肾功能不全对结果的干扰，目的为了探讨预测肝移植术后早期AKI的灵敏指标。</p><p>血清胱抑素C (cystatinC, CysC)，全名为血清半胱氨酸蛋白酶胱抑素C。它是一种低分子量蛋白，由全身有核细胞以恒定速率产生。可以通过肾小球自由滤过，并被近端肾小管重新吸收并代谢分解 [<xref ref-type="bibr" rid="hanspub.42761-ref10">10</xref>]。与常用的肾损伤标准物肌酐不同的是，血清胱抑素C不受性别、年龄、食物摄入种类和恶性肿瘤以及肌肉含量等相关因素影响，主要由肾小球滤过率决定。因此可以认为相比于肌酐，CysC是更接近于估计GFR的理想内源性生物标志物 [<xref ref-type="bibr" rid="hanspub.42761-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.42761-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.42761-ref13">13</xref>]。既往有研究表明，血清CysC可预测肝硬化患者AKI的发生和病死率，并且准确性高于血清肌酐 [<xref ref-type="bibr" rid="hanspub.42761-ref14">14</xref>]。而在心脏的体外循环术后，血清胱抑素c可作为术后急性肾损伤发生的危险预测因子 [<xref ref-type="bibr" rid="hanspub.42761-ref15">15</xref>]。在肝移植领域，有研究表明，术前血清胱抑素C可作为评估肝脏移植术后长期生存率的工具，而术前血清肌酐浓度则无法预测肝脏移植术后受者生存情况 [<xref ref-type="bibr" rid="hanspub.42761-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.42761-ref17">17</xref>]。但血清胱抑素C其在肝移植术前患者中是否具有预测AKI的能力目前仍有争议。</p><p>本研究通过监测肝移植围手术期患者血CysC的水平，明确血CysC对肝移植术后患者AKI的预测价值。结果显示，AKI组术前血胱抑素C高于非AKI组，差异有统计学意义。提示术前肾功能正常的肝移植患者存在有血清胱抑素异常，这些患者术前可能已存在潜在的肾损害，因此术前血胱抑素c可作为预测肝移植术后早期AKI的指标。ROC曲线表示术前CysC ≥ 0.98 mg/L，需警惕移植术后肾功能不全的发生。而移植术后1，2，3天CysC，急性肾损伤与非急性肾损伤两组之间的差异性显著。为早期预测肾功能不全发生，选取术后第一天的CysC作为预测术后AKI发生的指标，术后血清CysC ≥ 1.10 mg/L需注意预防移植术后肾功能不全的发生。</p><p>根据本研究结果，建议临床工作时对于需要肝移植的患者，有条件时应在围手术期监测CysC的水平，能有效地预测术后AKI的发生，并能够提前进行干预治疗，以改善患者的预后。本研究为回顾性分析，资料有限，样本例数较少，可能存在偏差，需要大规模的前瞻性研究去证实。本研究纳入的患者均为肝移植术后的患者，CysC对于其他疾病引起的AKI是否具有预测价值，尚待更多研究证明。而对于近年来急性肾损伤领域发现的其他的生物学指标，如N-乙酰-β-D-葡萄糖苷酶(NAG)、中性粒细胞明胶酶相关载脂蛋白(NGAL)、肾损伤分子1(KIM-1)、血清白细胞介素-18P等对肝移植术后患者AKI的预测价值本研究未能纳入 [<xref ref-type="bibr" rid="hanspub.42761-ref18">18</xref>]，需要更多的临床研究验证。</p><p>综上所述，肝移植术前Scr正常的终末期肝病患者仍然存在潜在的肾损害，术前血胱抑素c可作为预测术后早期AKI的灵敏指标。</p></sec><sec id="s9"><title>文章引用</title><p>杨晓蒙,杨通旺,代增强,杨鹏翔,陈德喜. 胱抑素C在肝移植术后急性肾损伤患者中的研究Cystatin C in Patients with Acute Kidney Injury after Liver Transplantation[J]. 临床医学进展, 2021, 11(05): 2422-2428. https://doi.org/10.12677/ACM.2021.115349</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42761-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kassel, C.A., Fremming, B.A., Brown, B.A. and Markin, N.W. (2020) 2019 Clinical Update in Liver Transplantation. Journal of Cardiothoracic and Vascular Anesthesia, 35, 1495-1502. &lt;br&gt;https://doi.org/10.1053/j.jvca.2020.01.056</mixed-citation></ref><ref id="hanspub.42761-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">郑树森, 沈恬, 徐骁, 王卓轶, 高峰, 凌琪. 中国肝移植受者肾损伤管理专家共识(2017版) [J]. 中华移植杂志(电子版), 2017, 11(3): 130-137.</mixed-citation></ref><ref id="hanspub.42761-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Tan, L., Yang, Y., Ma, G., et al. (2019) Early Acute Kidney Injury after Liver Transplantation in Patients with Normal Preoperative Renal Function. Clinics and Research in Hepatology and Gastroenterology, 43, 475-482.  
&lt;br&gt;https://doi.org/10.1016/j.clinre.2018.07.009</mixed-citation></ref><ref id="hanspub.42761-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Luft, F.C. (2021) Biomarkers and Predicting Acute Kidney Injury. Acta Physiologica, 231, e13479.  
&lt;br&gt;https://doi.org/10.1111/apha.13479</mixed-citation></ref><ref id="hanspub.42761-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kellum, J.A. and Lameire, N., for the KDIGO AKI Guideline Work Group (2013) Diagnosis, Evaluation, and Management of Acute Kidney Injury: A KDIGO Summary (Part 1). Critical Care, 17, Article No. 204.  
&lt;br&gt;https://doi.org/10.1186/cc11454</mixed-citation></ref><ref id="hanspub.42761-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Trinh, E., Alam, A., Tchervenkov, J. and Cantarovich, M. (2017) Impact of Acute Kidney Injury Following Liver Transplantation on Long-Term Outcomes. Clinical Transplantation, 31, e12863. &lt;br&gt;https://doi.org/10.1111/ctr.12863</mixed-citation></ref><ref id="hanspub.42761-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Umbro, I., Tinti, F., Scalera, I., et al. (2016) Acute Kidney Injury and Post-Reperfusion Syndrome in Liver Transplantation. World Journal of Gastroenterology, 22, 9314-9323. &lt;br&gt;https://doi.org/10.3748/wjg.v22.i42.9314</mixed-citation></ref><ref id="hanspub.42761-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Yin, Z., Li, B., Zou, F., Li, H. and Wang, X. (2017) Risk Factors of Acute Kidney Injury after Orthotopic Liver Transplantation in China. Scientific Reports, 7, Article No. 41555. &lt;br&gt;https://doi.org/10.1038/srep41555</mixed-citation></ref><ref id="hanspub.42761-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">白明传, 邬步云, 许雪强, 毛慧娟. 肝移植术后早期急性肾损伤的危险因素及与预后的关系[J]. 中华肾病研究电子杂志, 2020, 9(5): 193-201.</mixed-citation></ref><ref id="hanspub.42761-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Benndorf, R.A. (2018) Renal Biomarker and Angiostatic Mediator? Cystatin C as a Negative Regulator of Vascular Endothelial Cell Homeostasis and Angiogenesis. Journal of the American Heart Association, 7, e010997.  
&lt;br&gt;https://doi.org/10.1161/JAHA.118.010997</mixed-citation></ref><ref id="hanspub.42761-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Pasala, S. and Carmody, J.B. (2017) How to Use... Serum Creatinine, Cystatin C and GFR. ADC Education &amp; Practice, 102, 37-43. &lt;br&gt;https://doi.org/10.1136/archdischild-2016-311062</mixed-citation></ref><ref id="hanspub.42761-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ferguson, T.W., Komenda, P. and Tangri, N. (2015) Cystatin C as a Biomarker for Estimating Glomerular Filtration Rate. Current Opinion in Nephrology and Hypertension, 24, 295-300. &lt;br&gt;https://doi.org/10.1097/MNH.0000000000000115</mixed-citation></ref><ref id="hanspub.42761-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Maiwall, R., Kumar, A., Bhardwaj, A., et al. (2018) Cystatin C Predicts Acute Kidney Injury and Mortality in Cirrhotics: A Prospective Cohort Study. Liver International, 38, 654-664. &lt;br&gt;https://doi.org/10.1111/liv.13600</mixed-citation></ref><ref id="hanspub.42761-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Chung, M.Y., Jun, D.W. and Sung, S.A. (2010) Diagnostic Value of Cystatin C for Predicting Acute Kidney Injury in Patients with Liver Cirrhosis. The Korean Journal of Hepatology, 16, 301-307.  
&lt;br&gt;https://doi.org/10.3350/kjhep.2010.16.3.301</mixed-citation></ref><ref id="hanspub.42761-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Saydam, O., Türkmen, E., Portakal, O., et al. (2018) Emerging Biomarker for Predicting Acute Kidney Injury after Cardiac Surgery: Cystatin C. Turkish Journal of Medical Sciences, 48, 1096-1103. &lt;br&gt;https://doi.org/10.3906/sag-1704-96</mixed-citation></ref><ref id="hanspub.42761-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Uguen, T., Jezequel, C., Ropert, M., et al. (2016) Pretransplant Renal Function According to CKD-EPI Cystatin C Equation is a Prognostic Factor of Death after Liver Transplantation. Liver International, 36, 547-554.  
&lt;br&gt;https://doi.org/10.1111/liv.12989</mixed-citation></ref><ref id="hanspub.42761-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">马玺. 基于术前血清胱抑素C的肝脏移植预后风险分析[D]: [硕士学位论文]. 杭州: 浙江大学, 2017.</mixed-citation></ref><ref id="hanspub.42761-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">比木赤布, 余佳, 王卫星. 肝移植术后早期急性肾损伤预测指标的研究进展[J]. 疑难病杂志, 2021(20): 203-206, 211.</mixed-citation></ref></ref-list></back></article>